Until recently—when Terry Kelly stepped up as CEO—Brand served as CEO for Perception Neuroscience. He still sits on its board of directors, though, along with Wilde.

Rao is also the Chief Medical Officer for GABA Therapeutics. And both Brand and ATAI Chief Medical Officer, Matthias Luz, are on GABA’s board of directors.

Brand and Rao are co-founders of Entheogenix Biosciences. And, Rao is the company’s current CEO. Brand is now a board member.

Brand also serves on the supervisory board at Innoplexus.

Those involved with ATAI have their fingers dipped in each other’s metaphorical pies from the top level, with Angermayer’s Apeiron Investment Group investing in his own life sciences company, ATAI, down to the ventures which ATAI is, in turn, funding.

Angermayer has had a quiet hand in moving and developing capital all the way down the line. But where did Angermayer get all this capital, in the first place? To hear him tell it on the “Danny in the Valley” podcast, it all started when he was 14 and created a tutoring business.

“I started tutoring and then I realized—[this] was maybe my first major capitalistic, if you wanna say it that way—economical, or entrepreneurial revelation, which was so simple. But, when you tutor, it’s practically you selling your service,” Angermayer said. “So, I was like, ‘How can you scale it?’ And, I started to employ people because I had a brand name, and people wanted to be tutored by me.”

Ah, the question that nags at the heart of every 14-year-old future neoliberal free-market think tank board member: “How can I scale this?”

From here, Angermayer began studying at university. In his early 20s, he became a “junior partner” at the biotech company Ribopharma, which two professors he met while on a scholarship were involved in. This company attained one of the first core patents on a technology that is now referred to as “RNAi,” or, RNA interference. It is a biological process in which RNA molecules inhibit gene expression or translation.

“Super simplified, you can block parts of the DNA out,” Angermayer said. “This is very basic technology which you could use, for example, to switch off the replication mechanism of a virus.” Other uses he discusses include the potential to switch off the roots of genetic diseases.

One of Ribopharma’s co-founders, Roland Kreutzer, told me that Angermayer was hired on at Ribopharma to provide “managerial expertise” and that he initially “served as a member of our supervisory board and made important contacts to several venture capital firms.” Kreutzer said that Angermayer was not a co-founder of Ribopharma, however, as is claimed in many of Angermayer’s biographies across the internet, including his ATAI Life Sciences bio.

Psymposia reached out to Angermayer for comment on his involvement in Ribopharma—and to learn what managerial experience and venture capital connections he had in his early 20s—but has not heard back as of the time of publishing.

Around 2003, Ribopharma merged with the U.S. company Alnylam Pharmaceuticals, which went public in 2004. During his appearance on the “Danny in the Valley” podcast, Angermayer said that this merger was what created his nest egg to start investing.

“That was the first liquidity event,” Angermayer said. “Then I decided to skip university—very cliche, as well—and, to become something between an entrepreneur and an investor.”

For a similarly murky origin story featuring a supposed biotech wunderkind, check out Elizabeth Holmes and Theranos.

From this point, Angermayer went on to invest in a number of companies and produce a few movies. Eventually, he formed Apeiron Investing Group in 2011. Through this platform, he began investing money into biotech, fintech, cryptocurrency, artificial intelligence, cyber security, media, real estate, and more.

Around this same time, Brand—the eventual CEO of ATAI—was interning at the global executive consulting firm McKinsey & Co., where he worked with Allianz financial services to develop financial literacy campaigns and social media strategies, according to LinkedIn. And, Wilde—the eventual co-founder of both COMPASS Pathways and ATAI—was getting ready to step up as CEO of another company he founded called Springlane, which wound up being one of Germany’s leading online specialty retailers for kitchen appliances. After a couple brief spurts at Rocket Internet and Fab.com, Brand found himself working at Springlane, too, in a number of C-level leadership roles.

Wilde and Brand worked at Springlane for the better part of the next seven years, and Angermayer continued investing and producing movies. But, somewhere in that time period, all three of them had powerful interactions with psilocybin.

For Wilde, he credits his involvement with COMPASS Pathways to an experience with psilocybin that he says fully relieved him of his previously-treatment-resistant depression.

Brand experienced a death in his family, which sent his wife into a deep depression. So, the two of them traveled to Amsterdam where she took a high dose of psilocybin and had a healing experience, Brand said at the 2020 Green Market Summit.

And Angermayer, who claims to have never so much as smoked a joint, had a psilocybin experience on a yacht, which sailed into a jurisdiction where such substances are legal. Or, it was in the Netherlands, as he said on “Danny in the Valley.” One of those, maybe. He calls this the single most important experience of his entire life, and it is something he can’t quite put into words.

Wilde became a co-founder of Compass Pathways in 2016 (though he wasn’t listed as such until a couple years later), with Angermayer as one of their earliest investors. Then, the three of them—Wilde, Brand, and Angermayer—co-founded ATAI Life Sciences in 2018 to push drugs like psilocybin to market in a medical setting.

If the money is any indication, ATAI won’t be going anywhere soon. What remains to be seen, though, is how nonprofits like MAPS will hold up with for-profit competition that can wildly outpace them in funding and development. And, what those for-profit companies will do with the knowledge they produce from their developments.

In the era of psychedelic research overseen by nonprofits like MAPS’, open science and research sharing have been the norms. Scientists and researchers have generally worked in nonprofit and academic settings and had no reason to wall one another off. Think of it like open source software—software that is open to the public, which results in constant updates, improvements, and expansions. With a shift to a for-profit system, there are financial incentives for increased privatization of knowledge.

When confronted about issues of exclusivity and privatization, for-profit COMPASS Pathways’ co-founder George Goldsmith told Fortune, “Our manufacturing contracts are exclusive, in line with standard industry practice.” I have a feeling that we will be seeing the “standard industry practice” line a lot from here on out. And, that’s the big issue: regardless of the beliefs of the players entering this space, the standard industry practices they are utilizing are fundamentally incompatible with the altruistic narratives that psychedelic pharmaceutical companies are peddling to the public.

As the psychedelic pharmaceutical wellness industry blooms (or withers), competitors to ATAI will emerge. And, in a closed-science world, the motives of entrepreneurs—regardless of their stated intentions—must be regarded with some level of suspicion. All that we can hope for as this transition of power occurs (and, my hopes are fairly low) is that those in charge, those with the money and power, will reflect on the context and history of the space they are commandeering. And, when they claim things like “patients over profits,” I hope it’s more than just public relations lip-service to get people like me to shut up.